<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25806" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Neurological Sequelae of Endocarditis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lee</surname>
            <given-names>Yi</given-names>
          </name>
          <aff>Harvard Medical School; Chung Shan Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Siddiqui</surname>
            <given-names>Waqas J.</given-names>
          </name>
          <aff>Drexel University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yi Lee declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Waqas Siddiqui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25806.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Endocarditis is inflammation or infection of the endocardium, the inner lining of cardiac valves and cardiac muscle. It most commonly results from bacterial infection, which is also known as infective endocarditis (IE). Non-infective endocarditis, also known as nonbacterial thrombotic endocarditis (NBTE) or marantic endocarditis, is caused by the aggregation of sterile vegetation at the native cardiac valves. Clinical manifestations of IE and NBTE differ due to the difference in pathology, the nature of the cardiac valves (i.e., prosthetic valves, rheumatic heart), structures of the heart, pathogens and immunologic status (i.e., Libman-Sachs endocarditis in SLE patients). There is a broad spectrum of complications associated with endocarditis, including cardiac, systemic infections, neurologic, pulmonary, and renal complications. This activity reviews the evaluation and management of neurological complications of endocarditis and reviews the role of the interprofessional team in managing patients with neurological sequelae in endocarditis.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the etiology of risk factors for developing neurological complications of endocarditis</p></list-item><list-item><p>Describe the epidemiology of neurological complications of endocarditis.</p></list-item><list-item><p>Review the treatment considerations for patients with neurological complications of endocarditis.</p></list-item><list-item><p>Explain the importance of improving care coordination amongst the interprofessional team members to improve outcomes for patients with endocarditis affected by neurological sequelae.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25806&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25806">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25806.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Endocarditis is inflammation or infection of the endocardium, the inner lining of cardiac valves and cardiac muscle. It most commonly results from bacterial&#x000a0;infection, which is also known as infective endocarditis (IE). Non-infective endocarditis, also&#x000a0;known as nonbacterial thrombotic endocarditis (NBTE) or marantic endocarditis, is&#x000a0;caused by the&#x000a0;aggregation&#x000a0;of sterile vegetation at the native cardiac valves.&#x000a0;Clinical manifestations of IE and NBTE differ due to the difference in pathology, the nature of the cardiac valves (i.e., prosthetic valves, rheumatic heart), structures of the heart, pathogens and immunologic status (i.e., Libman-Sachs endocarditis in SLE patients).&#x000a0;There is a&#x000a0;broad spectrum of complications associated with endocarditis, including cardiac, systemic infections, neurologic, pulmonary, and renal complications. Heart failure is the most common cause of&#x000a0;death due to infective endocarditis.&#x000a0; After cardiac complications, neurologic sequelae are the second most common complications of IE.<xref ref-type="bibr" rid="article-25806.r1">[1]</xref> In NBTE, embolism is the most common clinical manifestation instead of cardiac complications.<xref ref-type="bibr" rid="article-25806.r2">[2]</xref></p>
      </sec>
      <sec id="article-25806.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Endocarditis is an infectious condition or inflammation of the cardiac valves or the endocardium.</p>
        <list list-type="bullet">
          <list-item>
            <p>Valvular disease such as rheumatic heart disease and congenital heart abnormalities like a bicuspid aortic valve, ventricular septal defect, coarctation of the aorta are risk factors for infectious endocarditis.&#x000a0;Pathogens that account for infectious endocarditis vary and depend on the risk factors including intravenous drug abuse, existing valvular dysfunction,&#x000a0;poor oral hygiene, and&#x000a0;dental procedure, immunocompromised status, the cardiac implantable electronic device (CIED), or previous history of infectious endocarditis. In infectious endocarditis, neurological complications correlate with the&#x000a0;size of vegetation and bacterial load. Among all the causative pathogens, Staphylococci aureus is&#x000a0;the most common microorganism of infective endocarditis in the United States and other developed countries.&#x000a0;Staphylococci aureus IE is significantly more likely to result in embolic events than other pathogens. Neurological sequelae from IE are&#x000a0;as following,&#x000a0;
<list list-type="order"><list-item><p>Embolic stroke is caused by vegetation debris&#x000a0;that lodge in the&#x000a0;cerebral blood vessels and ended up resulting in infarction;&#x000a0;</p></list-item><list-item><p>Transient ischemic attack (TIA) is an&#x000a0;episode of neurologic dysfunction&#x000a0;attributed to&#x000a0;ischemia of brain, spinal cord, or retina;</p></list-item><list-item><p>Cerebral hemorrhage</p></list-item><list-item><p>Meningitis</p></list-item><list-item><p>Brain abscess</p></list-item><list-item><p>Toxic encephalopathy</p></list-item><list-item><p>Seizure</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Nonbacterial thrombotic endocarditis is associated with connective tissue disorders, autoimmune disorders, malignancy, and other hypercoagulable states. Vegetations in NBTE are usually small and can easily dislodge compared to IE. Hence, NBTE with vegetations has an increased risk of developing&#x000a0;cerebral microemboli events and&#x000a0;intracranial&#x000a0;lesions.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25806.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <list list-type="bullet">
          <list-item>
            <p>Neurologic sequelae are the most common extra-cardiac complications in infectious endocarditis, which has been consistent over the past two decades.&#x000a0;Neurologic complications present in twenty-five up to forty percent of infective endocarditis.<xref ref-type="bibr" rid="article-25806.r3">[3]</xref> In one retrospective&#x000a0;study, approximately half of the patients with infective endocarditis developed&#x000a0;neurologic sequelae as the first sign. Significant cerebral embolisms (49%) are the leading neurologic complications followed by a transient ischemic attack (18%).<xref ref-type="bibr" rid="article-25806.r3">[3]</xref> Vegetations as big as 10mm or more are a risk factor for embolization.<xref ref-type="bibr" rid="article-25806.r4">[4]</xref> There is a high frequency of neurologic complications associated with endocarditis that contribute to high morbidity and mortality rates.<xref ref-type="bibr" rid="article-25806.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Approximately 80% of NBTE attributed to&#x000a0;advanced underlying&#x000a0;malignancy, whereas systemic lupus erythematosus is the second most common cause. Of note, up to half of the NBTE patients develop systemic emboli, which is the most common clinical manifestation rather than cardiac complications.<xref ref-type="bibr" rid="article-25806.r2">[2]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25806.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <list list-type="bullet">
          <list-item>
            <p>Current studies propose a combination of factors leading pathophysiological mechanisms. Injury-thrombus-infection theory and injury of endothelium with thrombotic vegetation following by bacterial adhesion are the generally accepted ideas for neurological complications in infectious endocarditis. Maiija H et al. reported that major cerebral embolisms account for 42% of neurologic episodes; 10% are cerebral hemorrhage, which is most likely due to anticoagulant therapy in patients with valvular diseases, septic arteritis, secondary hemorrhagic transformation of infarction or mycotic aneurysm rupture.<xref ref-type="bibr" rid="article-25806.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Several studies reported neurological events in cancer patients with NBTE; emboli travel to the central nervous system resulted in cerebral infarction or transient ischemic attack even though the most common sites of embolization are the spleen, kidney,&#x000a0;and extremities.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25806.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Embolism is the most common neurological&#x000a0;complications in both IE and NBTE. However, a wide range of clinical manifestations can occur.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Twenty to&#x000a0;forty percent of patients with infectious endocarditis present with symptomatic neurological sequelae such as stroke, TIA, meningitis, or brain abscess. Patients may present neurological complications before or after the diagnosis of infectious endocarditis.<xref ref-type="bibr" rid="article-25806.r5">[5]</xref> Hence, it is crucial to consider infectious endocarditis as one of the differentials in patients with unexplained fever accompanying neurologic signs. The diagnosis of infectious endocarditis is according to modified Duke criteria, which includes&#x000a0;<italic toggle="yes">clinical manifestations, blood cultures, and echocardiography</italic>. A blood culture may be negative in infective endocarditis, also known as culture-negative endocarditis, previous antibiotic treatments, or living in developing countries are risks factors for culture-negative endocarditis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patients with NBTE are often asymptomatic. Previous autopsy study&#x000a0;in cancer patients reported an approximately fifteen percent of cerebral vascular diseases, while only less than ten percent of patients experienced clinical neurological manifestations, e.g., stroke with focal neurological deficits, delirium, change of mental status.&#x000a0;Fever is uncommon. However, the majority of NBTE patients have an advanced underlying malignancy or autoimmune diseases such as SLE; therefore, patients might present as febrile.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25806.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnosis of infectious endocarditis has its basis on modified Duke criteria; therefore,&#x000a0;studies of microorganism and echocardiography are necessary for a definitive diagnosis. Whereas definitive diagnosis for NBTE is only genuinely possible pathologically, yet valvular vegetations on echocardiography without systemic infection serve strong evidence for NBTE.&#x000a0;The majority of endocarditis patients develop silent cerebral embolism. However, neurological sequelae are a poor prognostic factor. Recommendations are that physicians should perform rapid neurologic screening physical examinations bedside, including mental status, i.e., patients orientation, the function of cranial nerves, motor system, and sensation. For unstable patients, a CT scan without contrast is the test of choice. Diffusion-weighted MRI (DWI) is preferable to conventional MRI due to its advantages in detecting acute onset ischemic lesions,&#x000a0;smaller lesions as well as differentiating acute/chronic lesions.&#x000a0;For patients presenting headache, neck stiffness, and fever, cerebrospinal fluid (CSF) study is necessary for further investigation for central nervous system infection such as meningitis and brain abscess.</p>
      </sec>
      <sec id="article-25806.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Patients should receive treatment according to their clinical manifestations and diagnoses. For patients with infectious endocarditis, proper antibiotic treatment for&#x000a0;native (NVE)&#x000a0;or prosthetic valve endocarditis (PVE) is the key to reducing mortality and morbidity.&#x000a0;Management for neurological sequelae in endocarditis varies. Here, we discuss treatment respectively as below,</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ischemic stroke:&#x000a0;</bold>&#x000a0;Currently, large trials of management for ischemic stroke in endocarditis are lacking.&#x000a0;Initiating early antibiotic treatment not only adequately control infection but also leads to less embolism and mortality rate. European Society of Cardiology recommended that warfarin replaced by heparin in PVE and cardiac surgery within 72 hours, if not contraindicated, reduce the rate of embolism<xref ref-type="bibr" rid="article-25806.r6">[6]</xref> The roles of anticoagulants, antiplatelet, or thrombolysis after embolic events are not well-established.&#x000a0;Few studies have suggested a fair outcome of intravenous recombinant tissue plasminogen activator; nevertheless, intravenous thrombolysis is currently not indicated for acute ischemic stroke in infectious endocarditis patients due to concerns for hemorrhage<xref ref-type="bibr" rid="article-25806.r7">[7]</xref>.&#x000a0;Acute ischemic stroke in endocarditis patients should be treated per guideline, acutely lowering blood pressure is associated with worse prognosis&#x000a0;with an exception for hypertension crisis, urgency, emergency, or other comorbidities. Patients with NBTE with or without&#x000a0;embolism, including CNS, spleen or other organs&#x000a0;should be anticoagulated, due to the nature of smaller and more fragile vegetations in NBTE. Treating the underlying malignancy or associated autoimmune conditions is the key to embolism prevention in NBTE patients.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Intracranial&#x000a0;hemorrhage:&#x000a0;</bold>Intracranial hemorrhages (ICH) in endocarditis, including NBTE and infectious endocarditis, can be categorized into three mechanisms: (1) hemorrhage after ischaemic stroke (2) ruptured mycotic aneurysm, or (3) undetermined etiology. Once ICH occurs, all anticoagulant and antiplatelet agents should be discontinued for a minimum of&#x000a0;two weeks; patients should also have treatment per guideline, i.e., blood pressure control, intracranial pressure management, the reversal of anticoagulation, deep venous thrombus prevention, prevention of aspiration pneumonia, seizure management, etc. Surgery in patients with ICH in endocarditis depends on the site of lesion and&#x000a0;the clinical course.</p>
          </list-item>
          <list-item>
            <p><bold>CNS infection (Meningitis, Brain abscess):&#x000a0;</bold>Brain abscess occurs mostly in critically-ill patients. Pneumococci account for 70% of bacterial meningitis in patients with infective endocarditis&#x000a0;even though pneumococci is the causative pathogen in less than two percent of infectious endocarditis. Early effective antibiotic therapy in infectious endocarditis reduces CNS infection. Adequate antibiotic coverage and adjunctive intravenous glucocorticoids&#x000a0;in some instances may reduce the following neurological complications from CNS infection.&#x000a0;</p>
          </list-item>
        </list>
        <p>The role of&#x000a0;cardiac surgery at an early stage to prevent embolism remains controversial&#x000a0;and&#x000a0;indications for early surgery to prevent embolism differ among studies. Overall, management for endocarditis patients with neurological sequelae requires a multidisciplinary team, including&#x000a0;infectious disease, cardiology, neurology, neurology surgery, and cardiac surgery specialists&#x000a0;to implement optimal treatment for patients.&#x000a0;</p>
      </sec>
      <sec id="article-25806.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Symptomatic neurological sequelae may present a wide range of clinical manifestations. Careful&#x000a0;investigation is necessary for nonspecific symptoms such as headache, vomiting, change of consciousness, etc. Cerebral embolism should be a consideration in cancer patients presented with psychiatric symptoms. Differential diagnosis as following,&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Depression</p>
          </list-item>
          <list-item>
            <p>Psychiatric diseases, psychosis, fluctuating mental status due to other medical conditions</p>
          </list-item>
          <list-item>
            <p>Aseptic meningitis, viral encephalitis</p>
          </list-item>
          <list-item>
            <p>Cavernous sinus syndromes</p>
          </list-item>
          <list-item>
            <p>Dissection syndromes</p>
          </list-item>
          <list-item>
            <p>Metastatic brain disease in cancer patients&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Cardioembolic stroke</p>
          </list-item>
          <list-item>
            <p>Cerebral aneurysms</p>
          </list-item>
          <list-item>
            <p>Subarachnoid hemorrhage</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25806.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Neurological sequelae indicate poor prognosis in endocarditis patients. Symptomatic patients with severe neurological deficits and intracranial hemorrhages have the worst outcome. Mortality and morbidity rate are strongly associated with the lesions, types, and extension of brain injury. Maija H. et al. reported no significant difference between patients with NVE and&#x000a0;PVE. Also,&#x000a0;although <italic toggle="yes">Staphylococcus aureus</italic> is more likely to develop cerebral embolism than other microorganisms, there is no difference in the mortality rate either<xref ref-type="bibr" rid="article-25806.r3">[3]</xref>. One study&#x000a0;reported the Glasgow Coma Scale and valvular repair as prognostic factors in overall mortality;&#x000a0;stroke alone was a strong predictor of mortality<xref ref-type="bibr" rid="article-25806.r8">[8]</xref>.&#x000a0;</p>
      </sec>
      <sec id="article-25806.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Neurological sequelae in endocarditis lead to further morbidities. Ischemic embolic&#x000a0;infarction might&#x000a0;lead to permanent neurological deficits and dysfunction. A mycotic aneurysm in infectious endocarditis may contribute to cerebral hemorrhagic stroke without adequate infection control. The seizure is secondary to brain abscess, embolic infarction, or intracranial hemorrhage, etc. Venous thromboembolism (VTE) due to immobilization&#x000a0;after stroke and neurological deficits such as aphasia, dysphagia,&#x000a0;urinary tract infection, urinary incontinence, and sexual dysfunction may also present.</p>
      </sec>
      <sec id="article-25806.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Endocarditis is inflamed or infected cardiac valve or heart lining. Risk factors are damaged heart valves, ongoing infection, prosthetic heart valves, advanced malignancy, systemic lupus erythematosus, etc. Clinical manifestations&#x000a0;in endocarditis vary from person to person. Most common neurologic sequelae in endocarditis is a stroke.&#x000a0;If a patient has the risk factors mentioned above, symptoms like difficulty speaking, muscle weakness, a headache may indicate further investigation for stroke or other neurological complications.&#x000a0;</p>
      </sec>
      <sec id="article-25806.s13" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Clinically, patients may present unspecific neurologic symptoms; many patients remain asymptomatic throughout the clinical course. It is crucial to bear in mind that neurological sequelae do not necessarily occur after the diagnosis of endocarditis. Complete workup, neurological screening exams, and close follow-up&#x000a0;are warranted.&#x000a0;Antimicrobial treatment is the cornerstone of infectious endocarditis management, whereas targeting the underlying diseases is also essential to reduce morbidity and mortality in NBTE. Of note,&#x000a0;in SLE patients, the disease activity does not correlate with NBTE and embolism. Management for endocarditis with ischemic stroke is debatable; however, thrombolysis&#x000a0;is generally not recommended despite a few successful case series. Cardiac surgery is the indication in most of the endocarditis patients; nevertheless, the timing for patients with neurological sequelae as well as its role in embolism prevention&#x000a0;remains controversial.</p>
      </sec>
      <sec id="article-25806.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Neurological sequelae are&#x000a0;the second most common&#x000a0;complications in infective endocarditis. Early antibiotic initiation&#x000a0;reduces the rate of embolism as well as other complications.<xref ref-type="bibr" rid="article-25806.r9">[9]</xref> [Level I]&#x000a0;Limited studies on&#x000a0;anticoagulant therapy, antiplatelet therapy or thrombolytic therapy&#x000a0;on embolism in patients with infectious endocarditis, according to 2015 American Heart Association (AHA), none of these therapies were indicated.<xref ref-type="bibr" rid="article-25806.r7">[7]</xref> [Level I]&#x000a0;In patients with acute ischemic stroke who are already on anticoagulation, anticoagulant discontinuation should be for two weeks. [Level I] For patients with NBTE, embolism is the most common complication of all. Patients with NBTE with or without&#x000a0;embolism, including CNS, spleen or other organs&#x000a0;should be anticoagulated, with exception to contraindications&#x000a0;such as&#x000a0;intracranial hemorrhages and ongoing bleeding. [Level I] In SLE or cancer patients, anticoagulation should continue regardlessly to prevent the recurrence of embolism. [Level III] Pharmacist specialty trained in infectious diseases should assist with antibiotic selection and management. The nurses should coordinate care, assist with patient and family education, and arrange regular follow up reporting untoward events to the clinical team leader.</p>
        <p>Patients with neurological sequelae to endocarditis require an interprofessional team approach, including physicians, specialists, specialty-trained nurses, and pharmacists, all collaborating across disciplines to achieve optimal patient results. [Level V]</p>
      </sec>
      <sec id="article-25806.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25806&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25806">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/neurological-sequelae-of-endocarditis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25806">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25806/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25806">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25806.s16">
        <title>References</title>
        <ref id="article-25806.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sotero</surname>
                <given-names>FD</given-names>
              </name>
              <name>
                <surname>Ros&#x000e1;rio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fonseca</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Ferro</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Neurological Complications of Infective Endocarditis.</article-title>
            <source>Curr Neurol Neurosci Rep</source>
            <year>2019</year>
            <month>Mar</month>
            <day>30</day>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>23</fpage>
            <pub-id pub-id-type="pmid">30927133</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>el-Shami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Streiff</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment.</article-title>
            <source>Oncologist</source>
            <year>2007</year>
            <month>May</month>
            <volume>12</volume>
            <issue>5</issue>
            <fpage>518</fpage>
            <page-range>518-23</page-range>
            <pub-id pub-id-type="pmid">17522239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nikoskelainen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Engblom</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kotilainen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Marttila</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kotilainen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Neurologic manifestations of infective endocarditis: a 17-year experience in a teaching hospital in Finland.</article-title>
            <source>Arch Intern Med</source>
            <year>2000</year>
            <month>Oct</month>
            <day>09</day>
            <volume>160</volume>
            <issue>18</issue>
            <fpage>2781</fpage>
            <page-range>2781-7</page-range>
            <pub-id pub-id-type="pmid">11025788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohananey</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mohadjer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pettersson</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Navia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shrestha</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Desai</surname>
                <given-names>MY</given-names>
              </name>
            </person-group>
            <article-title>Association of Vegetation Size With Embolic Risk in Patients With Infective Endocarditis: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Intern Med</source>
            <year>2018</year>
            <month>Apr</month>
            <day>01</day>
            <volume>178</volume>
            <issue>4</issue>
            <fpage>502</fpage>
            <page-range>502-510</page-range>
            <pub-id pub-id-type="pmid">29459947</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merkler</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Lerario</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Navi</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Temporal relationship between infective endocarditis and stroke.</article-title>
            <source>Neurology</source>
            <year>2015</year>
            <month>Aug</month>
            <day>11</day>
            <volume>85</volume>
            <issue>6</issue>
            <fpage>512</fpage>
            <page-range>512-6</page-range>
            <pub-id pub-id-type="pmid">26163428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Horstkotte</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Follath</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Gutschik</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lengyel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pavie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soler-Soler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thiene</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>von Graevenitz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Priori</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Blanc</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Budaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cowie</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Deckers</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez Burgos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lekakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lindahl</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mazzotta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Morais</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Smiseth</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Lekakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vahanian</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Delahaye</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Parkhomenko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Filipatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Aldershvile</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vardas</surname>
                <given-names>P</given-names>
              </name>
              <collab>Task Force Members on Infective Endocarditis of the European Society of Cardiology</collab>
              <collab>ESC Committee for Practice Guidelines (CPG)</collab>
              <collab>Document Reviewers</collab>
            </person-group>
            <article-title>Guidelines on prevention, diagnosis and treatment of infective endocarditis executive summary; the task force on infective endocarditis of the European society of cardiology.</article-title>
            <source>Eur Heart J</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>267</fpage>
            <page-range>267-76</page-range>
            <pub-id pub-id-type="pmid">14972429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baddour</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Tleyjeh</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Rybak</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Barsic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lockhart</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Gewitz</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Levison</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bolger</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Steckelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Baltimore</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Fink</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>O'Gara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Taubert</surname>
                <given-names>KA</given-names>
              </name>
              <collab>American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council</collab>
            </person-group>
            <article-title>Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2015</year>
            <month>Oct</month>
            <day>13</day>
            <volume>132</volume>
            <issue>15</issue>
            <fpage>1435</fpage>
            <page-range>1435-86</page-range>
            <pub-id pub-id-type="pmid">26373316</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thuny</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Avierinos</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tribouilloy</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Giorgi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Casalta</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Milandre</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brahim</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nadji</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Riberi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Collart</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Renard</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Raoult</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Habib</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study.</article-title>
            <source>Eur Heart J</source>
            <year>2007</year>
            <month>May</month>
            <volume>28</volume>
            <issue>9</issue>
            <fpage>1155</fpage>
            <page-range>1155-61</page-range>
            <pub-id pub-id-type="pmid">17363448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25806.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dickerman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Abrutyn</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barsic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bouza</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cecchi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moreno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Doco-Lecompte</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Fortes</surname>
                <given-names>CQ</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>VG</given-names>
              </name>
              <name>
                <surname>Lerakis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Miro</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Rubinstein</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sexton</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Suter</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tornos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verhagen</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Cabell</surname>
                <given-names>CH</given-names>
              </name>
              <collab>ICE Investigators</collab>
            </person-group>
            <article-title>The relationship between the initiation of antimicrobial therapy and the incidence of stroke in infective endocarditis: an analysis from the ICE Prospective Cohort Study (ICE-PCS).</article-title>
            <source>Am Heart J</source>
            <year>2007</year>
            <month>Dec</month>
            <volume>154</volume>
            <issue>6</issue>
            <fpage>1086</fpage>
            <page-range>1086-94</page-range>
            <pub-id pub-id-type="pmid">18035080</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
